Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma
2011-004168-30Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Jun 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Pazopanib arm with Doxorubicin arm (2 arms). Primary endpoint: Progression-Free Survival. Started Jun 2012; status: completed.
02
Drugs
pazopanibdoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2011-004168-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004168-30.